According to recent trials, a significant number of patients do not have a completely effective response to clopidogrel. The aim of the study was to evaluate the rate of clopidogrel resistance in the context of important clinical characteristics and to specifically determine the relation between clopidogrel efficacy and biomarkers of inflammation. Consecutive non-selected patients following PCI were enrolled into the study. All patients received a loading dose of 600 mg of clopidogrel. The effect of clopidogrel was assessed using the VerifyNow assay 24 h after clopidogrel administration, clopidogrel resistance was defined as PRU ≥ 240. At the same time, standard parameters of biochemistry and hematology, the concentration of anti-inflammatory cytokine interleukin-10 and of soluble CD40 ligand, were measured. 378 patients were enrolled. 243 (64.3%) patients were responders (R) and 135 patients (35.7%) were non-responders (NR). Non-responders were older (R 65.7 ± 13.3, NR 69.8 ± 11.5, P < 0.05), had a higher prevalence of diabetes (R 26.3%, NR 38.5%, P < 0.05), were more often on mechanical ventilation (R 0.8%, NR 4.4%, P < 0.05). The leukocyte count (R 9.8 ± 3.5, NR 11.7 ± 12.8, P < 0.05), and concentration of IL-10 (R 3.1 pg/ml, NR 5.7 pg/ml, P < 0.05) was higher among non-responders. The concentration of CD40L was not significantly different between the groups. In a multivariate logistic regression, older age, higher weight, female gender, mechanical ventilation, and a higher concentration of leukocytes and IL-10 were associated with an increased risk for being a non-responder. Older, obese patients, especially women had a higher risk of high on-treatment-platelet-reactivity. Higher concentrations of leukocytes and interleukin-10 were also an important factor associated with the risk of low clopidogrel responsiveness.

Cardiocenter 3rd Internal Cardiology Clinic 3rd Medical School Charles University and University Hospital Kralovske Vinohrady Srobarova 50 Prague Czech Republic

Zobrazit více v PubMed

Clin Cardiol. 2009 Oct;32(10):561-8 PubMed

Am Heart J. 2008 May;155(5):806-16 PubMed

Platelets. 2001 Mar;12(2):74-82 PubMed

Clin Sci (Lond). 2009 Apr;116(8):651-8 PubMed

Circulation. 2003 Apr 29;107(16):2109-14 PubMed

Circulation. 2009 Jan 20;119(2):237-42 PubMed

Catheter Cardiovasc Interv. 2010 Feb 1;75(2):158-66 PubMed

J Cardiovasc Pharmacol. 2009 May;53(5):368-72 PubMed

Heart. 2011 Oct;97(20):1661-7 PubMed

Circ J. 2007 Jul;71(7):1086-91 PubMed

JAMA. 2002 Nov 20;288(19):2411-20 PubMed

Circulation. 2003 Sep 2;108(9):1049-52 PubMed

Angiology. 2012 Jan;63(1):62-6 PubMed

J Am Coll Cardiol. 2008 Sep 30;52(14):1128-33 PubMed

JAMA. 2011 Mar 16;305(11):1097-105 PubMed

J Am Coll Cardiol. 2002 Nov 20;40(10):1761-8 PubMed

Eur Heart J. 2008 Apr;29(8):992-1000 PubMed

N Engl J Med. 2005 Mar 24;352(12):1179-89 PubMed

Circ Cardiovasc Interv. 2010 Jun 1;3(3):277-83; discussion 283 PubMed

JAMA. 2010 Feb 24;303(8):754-62 PubMed

JAMA. 2009 Aug 26;302(8):849-57 PubMed